All News
Methotrexate - an old trusted friend who deserves better
Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.
Read Article
The Importance of Identifying Central Pain in PsA
Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy.
https://t.co/5fjNTrQvNx https://t.co/E1ivkK2bFz
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Zoster Management and Vaccination
Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy.
https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU
Dr. Antoni Chan synovialjoints ( View Tweet)
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
One new overarching principle for @eular_org PsA recommendations:
“The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile”
Wonder what triggered that
#EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za
David Liew drdavidliew ( View Tweet)
Central sensitization of neuropathic pain in #PsA - patient reported outcomes.
114 pts. And 22 percent with fibromyalgia
Pts with neuropathic pain didnt reach low disease activity or remission.
@RheumNow #EULAR2023 highlights! https://t.co/Gxkcrruamp
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new!
- 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline)
- safety now to to considered!
- consider the full picture - extraarticular manifestations
@rheumnow https://t.co/7GBILtCX4i
Bella Mehta bella_mehta ( View Tweet)
meds for PsA at #EULAR2023 recommendations
bDMARD after csDMARD (no order proposed)
@RheumNow https://t.co/bHMG4A8nmP
Bella Mehta bella_mehta ( View Tweet)
The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations
“A little bit of a paradigm shift here” - Laure Gossec
2023 @eular_org recommendations
#EULAR2023 @RheumNow https://t.co/gr9IOg1bbj
David Liew drdavidliew ( View Tweet)
Which bDMARD first in PsA?
2023 @eular_org recommendation: no preferred order. All are equal in its eyes
#EULAR2023 @RheumNow https://t.co/6HNNamAj1J
David Liew drdavidliew ( View Tweet)
PsA recommendations update at #EULAR2023
New overarching principles - should take account of safety
@rheumnow https://t.co/rrZ0ViFRPs
Bella Mehta bella_mehta ( View Tweet)
Here are the PsA drugs that have come to market in recent years
(and what a few years it’s been)
#EULAR2023 @RheumNow https://t.co/asFsHAD21y
David Liew drdavidliew ( View Tweet)
PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zaieEHN6sW
Bella Mehta bella_mehta ( View Tweet)
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Links:
Dr. John Cush RheumNow ( View Tweet)
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
Let le introduce you to ARTHUR 🤖
A very skilled robot who scans your hands and wrists in 15 mn 🤚
Amazing to see new #AI developments that will make our lifes’ easier!
#EULAR23 @ROPCA3 @JustSoren Stand M6
@RheumNow https://t.co/7PtR2CGqTt
Aurelie Najm AurelieRheumo ( View Tweet)
We need to assess CV risk in IA but how?
Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO
Bummer: these 3 prediction tools are less accurate in IA but also OA.
We need a dedicated tool.
@Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
